Why Attend?
Now in its 8th year, Animal Health, Nutrition and Technology Innovation Europe is the sector’s premier Innovation Summit showcasing the most exciting investment opportunities globally and connecting businesses with investors and strategic corporate partners. Our mission is to engage all key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today.
Following overwhelming feedback from the market, we have significantly expanded our programme this year with new focused content on nutrition and technology, alongside our production and companion animal health content. We will be running 4 separate innovation showcases in production animal health, companion animal health, nutrition, and technology.
Our new programme will address the full extent of this ever-evolving market. We are excited to provide an innovation platform that is bigger than ever and to continue to play a critical role in shaping the future of the animal health industry by presenting the most exciting innovations in prediction, prevention, and cure.
Book now to come and see for yourself!
Innovation Showcase
The Innovation Showcase is back for 2023!
The showcase is a unique opportunity for emerging companies with amazing technology to pre-sent in front of the industry’s most influential figures and investors.
Applications open summer 2022 so check back for updates!
2022 Speakers
Jeff Simmons
Justine Conway
Jasmeet Kaler
Dr Sam Hoste
Dr Sam Hoste, through Quantech Solutions, has undertaken Agri-Tech leadership roles in business, central government and global consultancy firms. He has led sector-wide animal health improvement initiatives; was instrumental in the establishment of the UK’s Agri-Tech Centres and COO of the Centre for Innovation Excellence in Livestock. He was a director and geneticist at ACMC and NPD, and UK Technical manager for PIC and a non-Exec at the Irish startup, Monford Ag. He is currently working with a number of UK and international Agri-tech companies that provide data, vision and emissions reduction opportunities for farmers and supply chains.
Jean Scheftsik de Szolnok
Mark Scott
Mark is Co-Founder and CEO of the pet wellness brand Bella & Duke which has become the largest DTC of natural pet food in just over 3 1/2 years in the UK.
Richard Hobson
Yemi Adesokan
Yemi Adesokan is Chief Scientific Officer and Co-Founder at Gnubiotics SA, a Lausanne, Switzerland biotech company pioneering the development of Human Milk Oligosacchrides (HMOs) for infants and adults as well as Animal Milk Oligosaccharides (AMOs) for companion animals. Yemi has been recognized for his innovative and pioneering work with awards such as the Boston Business Journal 40 under 40 award and the MIT Technology Review’s annual list of 35 top global innovators under the age of 35 TR35. Yemi has a PhD in Chemistry from the University of California, Irvine and completed a post-doctoral fellowship in Genetics with George Church at Harvard Medical School.
Robert Dawson
Ryan William Honaker, PHD
David Speller
Dr. Jamie Crittall
Jamie qualified from Bristol Vet School in 1993. He owns two separate UK veterinary practices – one, a family-owned 147-year old multi-branch practice and the other, a 9-year old start-up (which he subsequently sold in December 2018), as well as global healthcare compliance technology company, Virtual Recall.
Co-Founded with fellow veterinarian, Charlie Barton, as a result of their vision to enhance the intimate bond between all owners & their animals. They help vets create more valued customer experiences and drive improved business performance, to deliver better health and financial outcomes. They currently have their patent-pending, communication solution, iRecall® installed in over 1750 practices across three continents. It enables practices to send their clients their own bespoke messages, completely automatically, ensuring every animal and every client receive the appropriate communication - including immediate feedback - every time.
iRecall® sent over 26 million automated and personalized messages by SMS, email & post this year to over 3.5 million clients. helping them to become better informed and more engaged in the health and well-being of their 5.3 million animals, driven by their vets’ recommendations. Improving compliance, adherence and greater practice loyalty, delivering a virtuous value circle. Additionally, iRecall® enhances practices’ digital reputations by capturing over 1 million Net Promoter Scores to date, with an average score of over 80, with promoters encouraged to provide written testimonials and online reviews.
During Lockdown, they developed a new direct-to-consumer solution, OurVet.Shop®. Providing practices with a simple, secure payment gateway to pay for in-clinic services & settling outstanding accounts as well as offering clients a new channel to purchase food and medicines (-including prescription) with home delivery.
Virtual Recall was acquired by Zoetis in July 2020, and Jamie is now Senior Commercial Director within within Zoetis’ newly-formed Digital Practice Services Business Unit.
Jamie also has an all-encompassing knowledge and love for the media, being vet on set for film, tv & commercials for twenty plus years and a 5-year sabbatical in British television. He appeared regularly as a vet on The Big Breakfast; Sky News; BBC1’s The Really Useful Show, and latterly, co-presenting Pet Rescue’s spin off series, Pet Rescuers and Pet Rescue Roadshow. He has radio broadcast countrywide and is a regular speaker at UK veterinary business, technology and marketing seminars, conferences and events. Jamie is a Trustee of the Petplan Charitable Trust. Married with three children and a menagerie of pets and he can often be found mountain biking around the Surrey Hills.
Thomas Tillett
Andy Peters
Dave Ross
Dawn Howard
Stephane Maddens
Ashley Kalinauskus
Anton Xavier
Simon Grammel
Cees Jan Hollander
Gavin Hodgson
Sven Arnouts
Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.
Duncan Lascelles
B. Duncan X. Lascelles
BSc, BVSC, PhD, MRCVS, CertVA, DSAS(ST), Diplomate ECVS, Diplomate ACVS
Professor of Surgery and Pain Management
Director, Comparative Pain Research and Education Centre
Translational Research in Pain Programme,
North Carolina State University College of Veterinary Medicine, Raleigh, NC, 27606, USA
After graduating from the veterinary program at the University of Bristol, U.K., with honors, in 1991 Dr. Lascelles completed a PhD in aspects of pre-emptive/perioperative analgesia at the University of Bristol. After an internship there, he completed his surgical residency at the University of Cambridge, U.K. He moved to Colorado for the Fellowship in Oncological Surgery at Colorado State University, then a period of post-doctoral research in feline pain and analgesia at the University of Florida, and is currently Professor in Small Animal Surgery and Pain Management at North Carolina State University. He is board-certified in small animal surgery by the Royal College of Veterinary Surgeons, the European College of Veterinary Surgeons, and the American College of Veterinary Surgeons.
He is director of the Comparative Pain Research and Education Centre (CPREC). His research program (Translational Research in Pain [TRiP]) is dedicated to answering critical questions about pain control and pain mechanisms through high quality, innovative research. His career has been focused on developing algometry methods (methods to measure pain) in spontaneous disease animal models (pets with naturally occurring disease), and probing tissues from well-phenotyped animals with spontaneous disease to understand the neurobiology, with a strong translational focus. The aim of his research is to improve pain control in companion animals, and facilitate analgesic development in human medicine. He has authored over 180 peer reviewed research papers and reviews and 190 research abstracts, as well as over 30 book chapters.
He has worked closely with industry partners in both animal and human health, helping to re-define the relationship between industry and academia. Through reviews and invited presentations he advocates for the use of spontaneous disease in animals to inform human therapeutic development. Recently, he organized a meeting of industry, academia, regulatory authorities (FDA) and the NIH to discuss measurement of chronic pain in companion animals and the application to human pain research (www.PAW2017.com), and is planning PAW2019. He is completing a year-long integrated sabbatical within a pain therapeutic company (Centrexion Therapeutics) that develops novel therapeutics for both humans and animals. He provides consulting services related to pain therapeutic development across all stages of animal therapeutic development, and for pre-clinical and Phase I stages of human therapeutic development.
Through his work in academia and industry, he contributes to and facilitates the development of novel pain therapeutics for companion animals, and advocates for the use of spontaneous disease in pets to inform human pain therapeutic development.
Maxime Madder
Mattie Yeta
Janet Helms
Robert Hof
Rob Kelly
Kevin Kessler
Jason Johnson, Phd
Linda Dixon
Linda Dixon’s research is focused on the functional genomics of African swine fever virus (ASFV) aimed at understanding mechanisms of immune evasion and pathogenesis and application of this knowledge to development of vaccines. This large DNA virus causes a haemorrhagic fever of pigs with a high socio-economic impact in affected countries. The lack of a vaccine limits options for disease control.
Linda’s group has focussed on research underpinning the development of effective vaccines. Their approach has been to determine genome sequences of virulent and attenuated (weakened) isolates to help define the molecular determinants of virulence and identify those genes involved in evading host defences. The group has characterised ASFV proteins that inhibit host pathways involved in activating the host’s defences. These include proteins that inhibit host gene expression (transcription) responses, signal molecule induction and stress-activated responses. This knowledge has been applied to the rational development of candidate live attenuated ASFV vaccines by targeted gene deletions.
In collaboration with the Vaccinology Group they have compared host responses in vitro (in glass) and in vivo (in animal) and induction of protective immune responses in pigs immunised with these gene manipulated and natural attenuated ASFV strains. The group has also collaborated with these groups and The Jenner Institute to screen ASFV antigens for those important in induction of protective immunity, in particular those which induce strong immune (CD8+ T cell) responses. This information will be applied to development of candidate virus-vectored vaccines.
In addition Linda provides advice on ASFV nationally to Defra and internationally as an OIE expert and is Chair of the Asfarviridae Study Group of the International Committee on Taxonomy of Viruses and a Jenner Institute Investigator.
Justin Sherrard
As Global Strategist Animal Protein, Justin Sherrard is responsible for the timely and agenda-setting analysis of issues of strategic importance to animal protein companies around the world.
In his research and client engagement, Justin focusses on business opportunities in animal protein through, for example, increased production efficiencies, better access to growth markets and stronger supply chain models.
Prior to his current role, Justin has worked at RaboResearch Food & Agribusiness as Global Manager Research, Global Strategist F&A Supply Chains, and General Manager of Food & Agribusiness Research for Rabobank in Australia and New Zealand. He joined Rabobank in 2009.
Justin has also worked as an independent advisor to leading blue chip companies, not-for-profit organisations and governments, applying his knowledge of food & agribusiness, energy and natural resources issues, including sustainability and climate change.
Justin has over 20 years of global experience having worked in Europe, the United States, Latin America, New Zealand as well as his native Australia. He holds a Master of Applied Science and Bachelor of Science from the University of New South Wales in Sydney, Australia.
Francois Maree
Scott Holmstrom
Martijn Adorf
Martijn Adorf has a career in life sciences companies in global, regional and executive management roles. Before joining Animal Health Concepts as CEO and shareholder in 2020, he partnered with investors and start-up/scale-up companies acting in the sustainable feed-food value chain. From 2013 until end 2017 he was at Nutreco (part of SHV) as Managing Director of the Business Unit Feed Additives and member of Nutreco’s Executive Committee. He led the global growth of the Selko’s feed additives business, focusing on reduction of antibiotics in livestock production, and the acquisition of Micronutrients (USA). From 2005 – 2013 he held various global management roles at Royal DSM, where his focus was on human nutrition ingredients for health. In the 1990s he was in AkzoNobel’s medical diagnostics group and eventually led their regional business in South-East Asia.
He is currently also member of the supervisory board at Vaneeghen, a 360-year-old Dutch food ingredient specialist.
Mr. Adorf holds an MSc in biochemistry from Radboud University Nijmegen, Netherlands.
Kathy Turner
Matt Dobbs
Pete Selover
Pawel Wielgus
Deborah Dullen
Alain Wille
Isabelle Delannoy
Andrew Knight
John Howie
Dr John Howie is CEO & Co-founder of Lintbells, makers of the UK’s number 1 joint supplement, YuMOVE. On a mission to give pets an active life for life, Lintbells has a large share of the UK market and is expanding into the US, European and Asian markets.
Holly Ganz
Ben Sweeney
Alan Mackay
Charles Hoare
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
Amanda Burkardt
Lauren Carde
Aleksandra Szopinska
Robert Hof
Gerald Behrens
Alan Beynon
Shail Thaker
Peter McCarthy
Avner Finger
Jason Scott
Heiner Lehr
Carel du Marchie Sarvaas
Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.
He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.
Carel is experienced in the interplay between regulatory, political and communications issues as they relate to science, innovation and policy. A Dutch national, he is married and has four children. He has lived in South Africa, Canada, Brussels, and Paris and holds degrees from the University of Leiden and Johns Hopkins University
Brian Axe
Michael Hemprich
Dr. Michael Hemprich has almost 20 years experience in the Animal Health Industry and prior to joining IDT-Biologika in March, 2014, he was Manager of Business Development and country Manager for Germany and Austria at Dechra Pharmaceuticals. Prior to joining Dechra, he held senior management positions including Vice President Global Business Development & R&D at LAB International (Montreal, Canada), Regulatory Affairs Manager at Intervet Innovation GmbH and International Technical Manager for Bremer Pharma GmbH.
Michael graduated as veterinary surgeon from the University of Giessen and earned a doctorate degree of Veterinary Medicine from the Ludwig-Maximilians-University Munich. He is also a Member of the Royal College of Veterinary Surgeons and has an executive MBA in Biotechnology.
Jamie Brannan
Ian Anderson
Fatou Sow
Julia Belaya
Julia heads international business development for Kinship, working to accelerate the growth of the Kinship portfolio in the UK, Europe and other key international markets. She drives new customer acquisition and revenue growth for Kinship’s portfolio of businesses by identifying strategic partners, investment opportunities and market gaps.
Prior to Kinship, Julia was the Global Head of Business Development at Plug and Play, the world's largest early stage investor, accelerator, and corporate innovation platform. During her time there, Julia grew the Digital Health program to over 20 leading corporate partners and locations all over the US, Europe, South America and Asia.
Kerli Ats
Daniel Baertschi
Mareese Keane
Theo Kanellos
Theo Kanellos is a veterinarian with postgraduate studies in business and life sciences to a PhD level. During his career he worked as a clinician, an academic, a governmental official and for the last fifteen years as part of the management within the Pharmaceutical Industry where he has held several strategic roles. He has managed research laboratories, business development transactions, scientific and multi-functional alliances teams and programmes in several organisations that have led to the spinoff of biotechnology companies, the award of significant scientific grants, the founding of major strategic partnerships and the registration and licensing of successful commercial products and services. In his current role as the Director of Commercial Alliances in Zoetis he establishes entrepreneurial partnerships with companies, VCs, universities, and governmental institutions, internationally. He holds a visiting professorship at the School of Health and Medicine at the University of Surrey and is a board member of the Pirbright Institute in UK, the Global Alliance for Livestock Veterinary Medicines (GALVmed) in Africa and head of the action groups of the One Health Platform. He is the author of more than 30 peered reviewed papers and has given numerous presentations in several national and international conferences. His articles have also featured in many trade and public media.
Tomas Norton
Joost Matthijssen
Laurent Genet
Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.
Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management.
With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.
David Christensen
Edward McGruder
Mathews Mmopi
Aaron Schacht
Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Jimmy Owens
Nicolas Besse
Philip Watson
Maye Walraven
Maye leads InnovaFeed’s Business Development team, she’s in charge of building value for customers by developing the company’s innovative products. As part of her role, she oversees InnovaFeed’s relationships with various stakeholders across the value chain, from feed manufacturers, to farmers, distributors, NGOs and certification bodies. Prior to joining InnovaFeed she worked at McKinsey & Company as part of the Sustainability and Resource Productivity practice in New York (USA) for 5 years and helped clients deploy sustainable business solutions. Maye has a Bachelor of Engineering from Centrale Paris (France) and a master’s in Business Sustainability from the University of Queensland (Australia).
Lisa Williams
Chris Howarth
Alasdair Cook
Alasdair “Alex” Cook is a veterinary epidemiologist with more than 25 years national and international experience in livestock animal health in Government, academic and development environments. He joined the new School of Veterinary Medicine in January 2013. Previously, he worked in the Animal Health and Veterinary Laboratories Agency (AHVLA) where he was a senior member of staff engaged in leading research and surveillance programmes as well as part of the senior management team formulating strategy and implementing change. His interest in epidemiology grew from working in farm animal veterinary practice in the UK and in preventive veterinary medicine. A decade of overseas experience in Yemen, Zambia and Mexico working with poor rural communities underlined the important role that veterinary epidemiology plays in supporting animals in sustainable livelihoods and poverty alleviation. A professional life engaged with and leading multi-disciplinary teams makes Alex a natural proponent of the One Health perspective.
Mark Davies
Mark Boddy
Ian Hamilton
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Melanie Munro
Stephen Ainscough
Emily Stein
Emily Stein, PhD. Founded Primal Health, LLC in 2017 to focus on improving the dental health of both humans and animals by producing oral microbiome modulation products. She has spent 12 years developing SMMRT technology at Primal Therapies, Inc., which is focused on using metabolic influences to re-engineer disease-causing bacterial biofilms into those that are health-promoting, to decrease inflammation and to improve outcomes. Prior to that, she spent 7 years as a research fellow at Stanford University in Rheumatology and Immunology focused on the neuro-endocrine-immune axis in autoimmune and chronic inflammatory diseases. She holds a Phd. in Microbiology from the University of California at Berkeley where she studied inter- and intra-cellular signalling pathways involved in stress response and community development in bacteria and received her B.S. in Microbiology and Immunology at the University of Iowa where she studied the interaction between M. tuberculosis and innate immune cells
Jolyon Martin
Nuala Summerfield
Spencer Swayze
Patricia Barclay
Roman Makovitskiy
Mo Langhi
Kugan Sathiyanandarajah
Chris van den Berg
Jean-Luc Troch
Dr. Lawrence Brown
Dr Lawrence Brown is a Sector Specialist (Animal Sciences & Aquaculture) for the Department for International Trade. His main focus is on inward investment into the UK but also assists with trade. Lawrence is a qualified veterinary surgeon and consultant, working with private and public sector clients through his consultancy company LJB Veterinary Services Ltd. He is an elected member of the British Veterinary Association's (BVA) Scottish Council and is studying for an Executive MBA at the University of Edinburgh.
Register your interest for 2023
Be the first to receive the 2023 agenda!
Fill out the short form and we'll send you the 2023 agenda as soon as it is released.
Register Your Interest
Advisory Board
Author:
Glenn David
Glenn David
Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Aaron Schacht
Prior to this role, Mr. Aaron Schacht was the Vice President of Global Research and Development / Regulatory Affairs at Elanco Animal Healthheld. Before that, he held the role of Global Brand Development Leader – Pain in Lilly Biomedicines. He was the global leader for product development and commercialization activities for LY2951742 – Lilly’s novel CGRP neutralizing antibody – a new potential treatment for prevention of Migraine and Cluster Headache. In 2012, Schacht joined Lilly Biomedicines as Senior Advisor – Strategy & Business Development for Lilly BioMedicines. His responsibilities included oversight of Therapeutic Strategy development, R&D Portfolio Management, and Business Development for Lilly BioMedicines – Lilly’s largest business unit. Past roles included serving as Executive Director, Global External R&D, at Eli Lilly and Company, where he was responsible for implementation of strategies which aim to leverage novel approaches to external partnerships to augment Lilly’s access to pharmaceutical innovation as well as Executive Director of LRL (Lilly Research Labs) Strategy, Portfolio Management and Project Management where he was responsible for strategic planning, R&D portfolio and project management. Prior to these roles, he was Director, Innovation Center in the eLilly organization where he focused on the exploration, incubation and implementation of new business models and capabilities relevant to the strategic evolution of the pharmaceutical industry. In 2002, during a short leave from Lilly, Mr. Schacht was co-founder, President and CEO of Artesian Therapeutics, a Gaithersburg, MD cardiovascular drug discovery start-up. Mr. Schacht began his career at Lilly in 1990 as a medicinal chemist, and spent 5 years in the laboratory working to discover pharmaceuticals to treat cardiovascular disorders. Schacht studied Organic chemistry at the University of Illinois, receiving his Bachelors of Science degree in 1990.
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Author:
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Jean-Luc Michel
After graduating from the University of Pharmacy of Lyon with a Doctorate and from EM Lyon Business School with an MBA, Jean-Luc Michel started his career by creating his own consultancy company. He joined the pharmaceutical industry in 1991 spending 10 years developing a solid expertise in consumer healthcare and nutrition. During this period, he held a variety of senior marketing and sales management positions in France at Monsanto (Searle) and at Johnson&Johnson / Merck & Co where he was an Executive Committee member of the French subsidiary.
In 2001, Jean-Luc joined Merial, a leader in the animal health industry, where he held some key senior roles, such as EMEA Marketing Director of the Companion Animal Global Enterprise; Head of Marketing EMEA; Executive Marketing Director (Pet Business) in the US; VP, Head of Pet Vet Business Unit; and in 2016 joined the Executive Committee of Merial as Head of Global Commercial Development.
After the acquisition of Merial by Boehringer Ingelheim, Jean-Luc was appointed Head of Global Companion Animal Strategic Business Unit and became a member of the Executive Committee of the Boehringer Ingelheim Animal Health Business Unit.
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
Kathy V. Turner
Ms. Turner has been Corporate Vice President of IDEXX since May 2014 and leads the Company’s Europe, Middle East and Asia (EMEA) Companion Animal Commercial Operations. Prior to joining the Company, from 1987 to May 2014, Ms. Turner held various leadership positions at Abbott Laboratories, Inc., a broad-based healthcare company that manufactures and markets pharmaceuticals, medical products and diagnostics. Most recently, Ms. Turner was Divisional Vice President of European Commercial Operations for the Diagnostics Division from 2011 to 2014, and prior to that, Divisional Vice President of Global Strategic Operations for the Diagnostics Division from 2007 to 2011. Ms. Turner holds a bachelor’s degree in marketing and advertising from Syracuse University.
Thomas Zerzan
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Linda Rhodes
Dr. Rhodes has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has 28 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine. She has an extensive background in physiology, veterinary medicine, and molecular biology. As a senior research fellow at Merck Research Laboratories for 10 years, she led pre-clinical biology evaluation of several marketed human drugs. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. She worked for Merial Ltd. as director of development projects, leading project teams developing novel compounds for a variety of indications and headed new technology assessment, leading the evaluation of licensing opportunities. In April 2001, she formed AlcheraBio, a consulting, marketing, communications and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies, with clients in the US, European Union, Canada and Australia. AlcheraBio was acquired in 2008 by Argenta, and in 2011, Dr. Rhodes accepted a position as CEO of Aratana Therapeutics, a company developing innovative new medicines for dogs and cats, and subsequently, when the company became public (PETX) served as its Chief Scientific Officer. During her tenure, development was completed on three new pet therapeutics: two new molecules with novel mechanisms of actions were approved by the FDA, and a third drug had FDA registration completed and was approved in August, 2016. She is currently retired and an independent consultant. She is a member of the Board of Directors of ImmuCell (NASDAQ: ICCC) and the Alliance for Contraception in Dogs and Cats, serves on the Scientific Advisory Board of the Found Animals Foundation. She is an adjunct faculty member in the Graduate Animal Science program at Rutgers University.
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.
Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management.
With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.
Laurent Genet
Laurent Genet joined Nutreco in 2007. He has held a variety of senior management positions in Europe and Asia related to livestock and aquaculture nutrition, health and farming.
Earlier in his career, Laurent worked internationally for the largest French feed producer. He is a Doctor of Veterinary Medicine. Laurent also studied at both the London Business School in the UK, and Affärshögskolan in Norway from which he earned qualifications in business management.
With a key focus on innovation, Laurent has contributed to Nutreco’s overarching purpose of feeding the future in numerous ways. He spearheaded the company’s first operations in Southeast Asia for both Trouw Nutrition and Skretting, as well as introducing shrimp as a new species for Skretting. Laurent also led the creation of NuFrontiers – Nutreco’s corporate venturing arm. Latterly, he has been heavily involved in identifying and bringing forward new initiatives in the fields of digital technologies, biotechnologies and alternative proteins. With 30 years of experience in animal nutrition, health and farming gained around the world, Laurent has a very clear understanding of the need to be able to look beyond current circumstances in order to prepare for the future.
Selection Committee
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
Charles Hoare
Charles is a healthcare focused investment banker with approximately 20 years’ experience with specialty pharmaceutical companies in the US and Europe. Previously Charles was Managing Director for the international healthcare team at BofA Merrill Lynch and currently leads Commerzbank’s global healthcare team. During this time he has advised multiple companies on public and private capital raises, debt financing, mergers, acquisitions and out-licensing transactions.
He has a particular focus on the veterinary healthcare sector, where he has been involved in transactions for almost all of the top 15 companies in the sector. Recent transactions include advising Virbac on the acquisition of the Sentinel and Sentinel Spectrum brands from Novartis, advising Lohmann Animal Health on its sale to Eli Lilly, advising Pharmaq on Permira’s investment in the company and assisting United Biomedical with creating a global strategic alliance for its swine vaccine portfolio.
Charles also chairs the Commercialisation committee of the London School of Hygiene and Tropical Medicine and serves on the school’s Finance and Planning committee. In addition, he is Chairman of the Bulldog Trust, which funds and supports entrepreneurial charities, and sits on the Boards of Directors of Placehill Limited (growth capital), Laguna Ventures Limited (late stage venture finance) and Atlantic Healthcare plc.
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
Matthias Hofer
Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Julia Stephanus
Julia Stephanus is a 30 year veteran of the veterinary pharmaceutical industry. Currently Julia is President of Avviare, a consulting firm specializing in supporting veterinary focused start-ups.
Julia has been involved in the development and launch of 28 veterinary products. She has been a senior executive in two start-up pharmaceutical companies (Aratana Therapeutics and Summit VetPharm), and held key positions at multi-nationals including Pfizer (now Zoetis) and its legacy companies.
As Chief Commercial Officer of Aratana Julia provided the commercial leadership resulting in a successful IPO (NASDAQ:PETX), high-impact corporate branding, innovative go-to-market strategies for five therapeutics and the staffing of the inaugural commercial organization.
As founder and CEO of Summit VetPharm, Julia developed and launched a new line of companion animal parasiticides, grew the company to a cash flow positive position with 85 employees in five years and divested the company to Ceva Animal Health in 2010. A graduate of Indiana University, she has continued her executive training at Harvard, Columbia, University of Chicago and the Wharton School of Business.
Claire is an Associate at Anterra Capital. Prior to joining Anterra, she was the Chief of Staff at Crestovo, a biotech start-up developing microbiome-based therapies for infectious diseases. Before that, she worked as a consultant at ClearView Healthcare Partners, where she advised pharmaceutical and biotech clients on a variety of growth strategy topics. She graduated from the Massachusetts Institute of Technology with Bachelor of Science degrees in biological engineering and management science.
Claire Smith
Claire is an Associate at Anterra Capital. Prior to joining Anterra, she was the Chief of Staff at Crestovo, a biotech start-up developing microbiome-based therapies for infectious diseases. Before that, she worked as a consultant at ClearView Healthcare Partners, where she advised pharmaceutical and biotech clients on a variety of growth strategy topics. She graduated from the Massachusetts Institute of Technology with Bachelor of Science degrees in biological engineering and management science.
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
Cynthia Cole
Dr. Cindy Cole is a Technical Partner at Digitalis Ventures and an Associate Clinical Professor at the University of Florida. Prior to joining Digitalis she was in the animal health industry for many years holding senior leadership and R&D roles at Mars Petcare, Novartis Animal Health, IDEXX, and Piedmont Pharmaceuticals. Dr. Cole completed her DVM and PhD at the University of Florida and was on the faculty of the University of California, Davis and UF.
Dino Dedic, CFA
Author:
Paul Dick
Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.
While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.
His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.
Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.
In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).
Paul Dick
Dr Paul Dick D.V.M. M.Sc. obtained his veterinary medical degree with honours in 1984.
While working in clinical practice he completed his Masters in Immunology and Virology transitioning into the Pharmaceutical industry in 1988. Dr. Dick has over 25 years experience in the pharmaceutical space including general management and leadership roles, business development, commercialization, regulatory affairs, and product development encompassing medicinal, non-medicinal and natural health products.
His work in this sector has ranged from small “start up” companies to medium and large multi-nationals functioning in various capacities from research to COO and CEO.
Dr. Dick has worked extensively with Health Canada and the Canadian Food Inspection Agency on numerous regulatory submissions and on several Departmental Committees.
In addition he has been a recipient of the NSERC Synergy Award and has served as a peer reviewer of NSERC strategic grants. He is currently heading his own consulting firm ( Paul Dick and Associates Ltd.) and is the managing partner and president of a venture capital partnership (Vet Venture Capital Inc.).
Duane Cantrell
Laëtitia Gerbe
Yorán is an Analyst at Anterra Capital. He is primarily responsible for deal sourcing and execution with a focus on digital technologies. He is also involved in portfolio management.
Prior to joining Anterra, Yorán was active as a researcher in the Creative Machines Lab at Columbia University, focused on developing novel cooking techniques for 3D food printing applications. Before that, he has worked at the process technology department at Heinz and the product and process development department at Cargill.
Yorán holds a MSc in Sustainable Food Process Engineering and a BSc in Food Technology from Wageningen University with a BSc minor in Food Business and Management from UC Davis.
Yorán Meijers
Yorán is an Analyst at Anterra Capital. He is primarily responsible for deal sourcing and execution with a focus on digital technologies. He is also involved in portfolio management.
Prior to joining Anterra, Yorán was active as a researcher in the Creative Machines Lab at Columbia University, focused on developing novel cooking techniques for 3D food printing applications. Before that, he has worked at the process technology department at Heinz and the product and process development department at Cargill.
Yorán holds a MSc in Sustainable Food Process Engineering and a BSc in Food Technology from Wageningen University with a BSc minor in Food Business and Management from UC Davis.
Benjamin Shaw
Nicky Deasy
Barry is a strategy consultant to the pharma, welfare, retail, tech and veterinary profession having previously held senior executive roles within the veterinary profession most recently an executive board role at CVS as Marketing and Commercial Director, the largest PLC veterinary group in Europe, a role which involved him developing and delivering marketing strategies for the organisation and its member practices and honing its commercial operations. This role saw him supporting growth and the integration of over 300 veterinary practices, crematoria, out of hours clinics and multi-disciplinary hospitals and bringing to market a number of own label prescription and non-prescription products.
Barry Brackner
Barry is a strategy consultant to the pharma, welfare, retail, tech and veterinary profession having previously held senior executive roles within the veterinary profession most recently an executive board role at CVS as Marketing and Commercial Director, the largest PLC veterinary group in Europe, a role which involved him developing and delivering marketing strategies for the organisation and its member practices and honing its commercial operations. This role saw him supporting growth and the integration of over 300 veterinary practices, crematoria, out of hours clinics and multi-disciplinary hospitals and bringing to market a number of own label prescription and non-prescription products.
Sébastien Lafon
Eli Hasson is founding partner of PHIL Ventures (Pet Health Innovation Labs) – the early-stage investments arm of Australia’s PETstock group.
Based in Tel Aviv, Eli has over 25 years’ experience in the Israeli tech sector – with deep knowledge in business strategy and multi-national operations. He was involved in multiple disruptive digital health ventures and led several technology mega-projects. Eli co-founded Quantum Discoveries – an industry-disrupting mineral exploration company that develops and deploys innovative technologies, operating in Chile and US.
Besides his passion for tech & innovation, Eli is an avid jazz musician and improviser.
Eli Hasson
Eli Hasson is founding partner of PHIL Ventures (Pet Health Innovation Labs) – the early-stage investments arm of Australia’s PETstock group.
Based in Tel Aviv, Eli has over 25 years’ experience in the Israeli tech sector – with deep knowledge in business strategy and multi-national operations. He was involved in multiple disruptive digital health ventures and led several technology mega-projects. Eli co-founded Quantum Discoveries – an industry-disrupting mineral exploration company that develops and deploys innovative technologies, operating in Chile and US.
Besides his passion for tech & innovation, Eli is an avid jazz musician and improviser.
In 2014, Matthieu founded Singapore-based VisVires New Protein (VVNP), the first venture fund in
Asia exclusively focused on finding disruptive solutions for our global food and feed system.
Unrestricted by geographical boundaries, VVNP strives to uncover impactful solutions that
address the unmet challenges of our food system. VVNP has evolved quite a bit since its inception.
It now operates two funds with a presence in Singapore and London. Its portfolio of 10 companies
includes Ÿnsect in France, In Ovo in the Netherlands, Aleph Farms in Israel, and Mushlabs in
Germany.
Matthieu has over 25 years’ experience in investment management. Most recently, as Senior
Managing Director, Director of Research as well as a member of the Executive and Investment
committees of Everest Capital. Prior to that, he was with Banque Paribas in Hong Kong, New York,
Taipei, and Paris.
Matthieu Vermersch
In 2014, Matthieu founded Singapore-based VisVires New Protein (VVNP), the first venture fund in
Asia exclusively focused on finding disruptive solutions for our global food and feed system.
Unrestricted by geographical boundaries, VVNP strives to uncover impactful solutions that
address the unmet challenges of our food system. VVNP has evolved quite a bit since its inception.
It now operates two funds with a presence in Singapore and London. Its portfolio of 10 companies
includes Ÿnsect in France, In Ovo in the Netherlands, Aleph Farms in Israel, and Mushlabs in
Germany.
Matthieu has over 25 years’ experience in investment management. Most recently, as Senior
Managing Director, Director of Research as well as a member of the Executive and Investment
committees of Everest Capital. Prior to that, he was with Banque Paribas in Hong Kong, New York,
Taipei, and Paris.
2022 Partners
Animal Health Innovation Europe is supported by the most influential bodies across the Animal Health, Nutrition and Veterinary industries.
Be one of them, communicate about the event to your network, spread the word and become a Supporter of the Animal Health, Nutrition and Technology Innovation series.
Headline Partner
Zoetis
Website: https://animalhealthlatam.com/events/animal-health-latam-2021
Website: www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
Associate Partners
Argenta
Website: www.argentaglobal.com
Founded in 2006 in New Zealand, Argenta’s talented and committed employees are dedicated to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States, the United Kingdom and Germany, Argenta holds a unique position as the only combined global contract research organization (CRO) and contract development and manufacturing organization (CDMO) dedicated to animal health.
Argenta operates from Molecule to Market in partnership with customers of all sizes from all corners of the world, supporting their research & development, clinical research, regulatory, scale up and manufacturing needs along their veterinary product development journey.
The day-to-day ethos that drives Argenta forward is a mission focused on global partnerships, a Molecule to Market approach, and innovation. At the core of the business and the organisation is collaboration —among the global employee base and with their customers.
Argenta proudly partners with a vast range of global clients. Our services and facilities scale to meet the requirements of the largest multinationals, while, at the other end of the spectrum, offer startups and small companies capabilities and solutions that help bring their ideas to fruition.
Elanco
Website: www.elanco.com
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we’re driven by our vision of Food and Companionship Enriching life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet.
GHO Capital
Website: ghocapital.com
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.
Ceva
Website: https://www.ceva.com/en
It’s estimated that a staggering 75% of all emerging human infectious diseases originate from animals and birds. These zoonoses, as they’re known, are what compel Ceva to innovate – to succeed in the fight against the likes of avian flu, brucellosis and Q-fever. They’re one of the driving forces behind our vision: ‘Together, beyond animal health’.
Ceva works with welfare and social programmes around the world to bring this vision to life – anywhere our products and know-how can make a difference and with all kinds of partners. From Uganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
They’re truly global, based in 46 countries and working across more than 110. We have 12 R&D centres, 25 production sites and more than 5000 employees worldwide.
Zoetis
Website: https://animalhealthlatam.com/events/animal-health-latam-2021
Website: www.zoetis.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.
For more information, visit www.zoetis.com.
IDEXX
Website: www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency, and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry, and testing for the quality and safety of water and milk. Headquartered in Maine, IDEXX employs more than 8,000 people and offers products to customers in over 175 countries.
Our purpose is to be a great company that creates exceptional long-term value for our customers, employees, and shareholders by enhancing the health and well-being of pets, people, and livestock.
For more information about IDEXX, visit: www.idexx.com
Gnubiotics
Website: https://gnubiotics.com/
Gnubiotics Sciences is a biotech company pioneering, research, development and industrialization of essential animal milk oligosaccharides (AMOs) to support companion animal GI, immune and microbiome health.
Start-Up Development Partner
Paul Dick and Associates
Website: https://pauldickassociates.com/
Paul Dick & Associates Ltd (PDA) was created in 2010 to meet the needs of large, medium and small animal health companies wishing to develop and commercialize new technologies and products. In 2017, PDA expanded into the human health space to offer its services to companies developing new technologies and services for the human health market.
PDA has a highly experienced team that, in combination with other partner organizations (Contract Research Organizations, Contract Development/ Manufacturing Organizations, Veterinary Colleges, Private Research Facilities), makes for a best in class Human and Animal Health consulting firm.
Knowledge Partner
McKinsey & Company
Website: https://www.mckinsey.com/
There was a time when economic growth, sustainability, and inclusion were seen as trade-offs, but leaders today need to achieve all three. This new paradigm of growth will be more sustainable, driving innovation while reducing environmental impact. It will also be more inclusive, creating access to opportunities for people worldwide.
This is not an easy task, but McKinsey & Company's ambition is to help organizations and their leaders make it a reality. They combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next.
Consulting Partner
Stonehaven Consulting
Website: https://www.stonehaven-consulting.com/
Gold Partners
Vetio Animal Health
Website: https://vetio.com/
As a Contract Development and Manufacturing Organization (CDMO) dedicated to Animal Health, Vetio integrates product development, analytical services, technical services, and commercial manufacturing of veterinary pharmaceuticals using a Quality-by-Design approach. Vetio is your single-source partner for successful product approval, scale-up, and ongoing commercial supply.
Vetio has provided expertise to animal health companies around the world since 2001 and is committed to the development and manufacturing of products that improve the lives of animals, while assuring the safety, quality and compliance of our products to the highest industry standards.
Ask Us about our intellectual property in pharmaceutical soft chews and palatability. Please visit www.vetio.com and watch our brief company overview video.
Clinglobal
Website: https://www.clinglobal.com/
CLINGLOBAL is an Animal Health Services company established during 2016 in Mauritius acting as a contract holding and centralised service provider for the ever expanding “Clin” group of companies.
Our unique business model allows the animal health industry and community to benefit from our simplified contracting solutions by having a customizable all-inclusive approach and the delivery of animal health research projects and services.
Klifovet
Website: www.klifovet.com
KLIFOVET provides high quality services for the animal health and animal nutrition industry regarding the registration and marketing of all kind of veterinary products. We support ambitious young biotech and veterinary pharma companies on their way to the top by providing full business and product development management, regulatory affairs consultancy including dossier writing, compilation and submission, and full CRO services for safety and efficacy studies. We are proud on 18 years of experience, well organized logistics, a highly motivated team, and a comprehensive net of co-operators and skilled investigators throughout Europe, North America and the world. We handle large multinational projects as professionally as national ones, complying to national, EMA, EFSA or FDA standards.
ZENOAQ
Website: http://www.zenoaq.jp/english/index.html
ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.
Aenova
Website: https://www.aenova-group.com/en/home
The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industries. As a full-service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes of pharmaceuticals and food supplements for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low dose, OEB 1-5, and Fill&Finish of biologics/vaccines up to BSL-2. Around 4,100 employees at 16 locations in Europe and the USA contribute to the company's success.
MSD Animal Health
Website: https://www.msd-animal-health.com/
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck.
Through its commitment to the Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services.
Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MSDAnimalHealth.
Animalcare Group
Website: https://www.animalcaregroup.com/
Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition
knoell
Website: https://www.knoell.com/en/markets/animal-health
knoell is the only knowledge-based animal health consultancy and clinical studies specialist with its own technical staff based on three continents: North America, Europe, and Asia. This means easy access and broad reach for you as our valued client into the animal health market. It also benefits you by avoiding duplication, providing a better return on investment for valuable data, improving control of expenditure, and reducing administration.
With the arrival of the two well-known and established brands Cyton and Triveritas in the knoell group, knoell was able to expand their business into the animal health market. Both companies have more than two decades of experience in the animal health market in Europe and the USA. The joint activities led to growth of the animal health business in Europe, the US and Asia as well. In order to strengthen its presence in the USA, knoell Animal Health LLC was founded in early 2020. Since February 2021, Triveritas operates as knoell Animal Health Ltd.
With animal health experts working in the US, Europe and Asia and an established network of trusted partners, knoell can support clients' business aspirations better than ever before and provide a truly global service.
Our animal health team offers a full portfolio of services, including start-to-finish product development and ad hoc services.
Phibro Animal Health Corporation
Website: www.pahc.com
Phibro Animal Health Corporation is one of the leading animal health companies in the world and is dedicated to helping meet the growing demand for animal protein. We are a global diversified animal health and mineral nutrition company. We concentrate exclusively on animals for food production and are one of the few global companies offering a comprehensive range of animal health and mineral nutrition products. For nearly 40 years we have been committed to providing livestock producers with value-based products and solutions to help them maintain and enhance the health of their animals. We develop, manufacture and market a broad range of products for food animals including poultry, swine, beef and dairy cattle and aquaculture. Our products help prevent, control and treat diseases, enhance nutrition to help improve health and contribute to balanced mineral nutrition.
ScoutBio
Website: https://www.scoutbio.co/
Scout Bio is a privately held biotechnology company revolutionizing pet medicine by delivering a pipeline of one-time gene therapies for major chronic pet health conditions. Scout Bio’s therapies are designed to induce long-term expression of therapeutic proteins in pet patients after a single injection. The novel single injection adeno-associated virus (AAV) vector treatments intend to improve treatment compliance, treatment outcomes, and the quality of life for companion animals by eliminating the need for daily or monthly administration. Therapeutic products target a number of major chronic diseases and markets, including diabetes, osteoarthritic pain, atopic dermatitis, and feline anemia associated with chronic kidney disease. Headquartered in Philadelphia, Pennsylvania, Scout Bio has a research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, a leader in the field of genetic medicine research.
Animal and Plant Health Agency
Website: https://www.gov.uk/government/organisations/animal-and-plant-health-agency
Please visit our website for more information.Kinship
Website: https://kinship.co/
Kinship is here to help everyone pet parent like a pro. Why? Because our pets make us better humans, and we owe them the best possible care. As the premier partner to a new generation of pet parents, we use our data, products, and services to help people be the best pet parents they can be. And we unite changemakers in pet care to break down barriers, open new doors, share insights, and advance our collective knowledge. All so we can reimagine the pet parenting experience, and up people’s confidence, and help the world find better ways to care.
Kinship is a coalition that includes WISDOM PANEL™, the world’s most accurate pet DNA test, WHISTLE™, an award-winning leader in smart monitors for pet health, THE WILDEST™, one destination that helps people ace it for their animals, Pet Insight Project, a pioneer in interpreting health data to improve pets’ lives, GoodFriend by Kinship, a platform that connects pet parents and care providers, and Adopt-a-Pet.com, a site that helps share homeless pets with millions of adopters. As well as partnerships like our Leap Venture Studio accelerator that supports innovators and start-ups, to bring new solutions to pet parents.
Together, our brands, teams, and partners work to set new standards in pet care. Kinship is a division on Mars Petcare
Leap
Website: https://www.leapventurestudio.com/
Michelson Found Animals and Kinship, a division of Mars Petcare, have partnered to launch the Leap Venture Studio & Academy: the first startup-centric program built to springboard innovation in the growing pet ecosystem. Together, the two companies represent the most innovative thinkers in the pet care industry. Michelson Found Animals & Kinship recognize the immense value of the pet care sector and want to foster innovation and growth from the bottom-up.
MFA
Website: foundanimals.org
Michelson Found Animals Foundation is a leading animal welfare non-profit that believes people and pets are better together. Generously funded by Dr. Gary Michelson and Alya Michelson, Found Animals operates a range of catalytic grants, impact investments, operating programs, and education and advocacy initiatives that share a common goal: to champion pets at every point they intersect with our society. Found Animals has helped more than 8 million pets since it was founded in 2005. Learn more at foundanimals.org.
vHive
Website: https://vhive.buzz
The University of Surrey is home to the School Veterinary of Medicine including Veterinary Health Innovation Engine (vHive) and Animal Health Innovation Network (AHIN). vHive is a research and innovation centre dedicated to the development and adoption of new digital technologies in animal health. It bridges the technology readiness level gap between the world’s leaders in animal health while leading in the development of transformational digital analytics tools to advance the wellbeing of animals for the benefit of society. vHive is comprised of both academic and commercial experts with the expertise necessary to carry out new, complex endeavours on behalf of partners who require academically verified output and bespoke business development.
AHIN acts as a catalyst, stimulating innovation in animal health through convening academia, research organisations and industry in a connected regional ecosystem of excellence.
Founding partners include The University of Surrey working with Enterprise M3 (EM3 LEP), The Pirbright Institute, Animal and Plant Health Agency, Veterinary Medicines Directorate and Sparsholt College. The network works alongside an ecosystem of industry partners including Zoetis and Mars Petcare and is recognised as High Potential Opportunity by the Department for International Trade for international investment and an asset to UK and global economies.
Pet Flavors
Website: https://www.petflavors.com/
PF, Inc. (Pet Flavors, Inc.) is the world leading developer and manufacturer of quality flavor bases for both pharmaceutical drugs and nutritional supplements in the animal health industry. PF Inc. sells several types of flavor bases for use in formulating palatable canine, feline, and equine dosage forms that are sold on a worldwide basis. PF’s Artificial Powdered Beef Flavor; PC-0125 is sold to 9 of the top 10 largest animal health pharmaceutical companies in the world and has been successfully formulated in over 20 New Animal Drug Approvals (NADAs). Our company has over 30 years of experience with formulation and product development. With an active ingredient and our flavor bases we can create highly palatable chewable tablets, soft chews or granules. Our services include improving the palatability of an existing product, creating product line extensions or developing entirely new products. Please visit our website www.petflavors.com for detailed information.
CosmosID
Website: www.cosmosid.com
CosmosID® provides end-to-end solutions unlocking the microbiome. A provider of CLIA-certified & ICH-GCP compliant NGS Services and Bioinformatics Solutions, CosmosID offers a range of validated and optimized workflows for research and development.
CosmosID also offers independently validated, industry-leading pipelines for processing metagenomic data, yielding multi-kingdom, strain-level resolution with leading sensitivity and precision. Results can be accessed via CosmosID-HUB, a user-friendly and interactive software for comparative analysis of microbiome data, complete with dynamic charts, visualizations, and statistics.
Single Use Support
Website: https://www.susupport.com/
Please visit our website for more information.Vetoquinol
Website: www.vetoquinol.co.uk
Founded in 1933, Vetoquinol is the 9th largest veterinary pharmaceutical business, committed to the protection and well-being of both animals and people.
Nutreco NuFrontiers
Website: www.nutreconufrontiers.com
Nutreco is a global leader in animal nutrition and aquafeed. Our advanced nutritional solutions are at the origin of food for millions of consumers worldwide. Nutreco employs over 12,000 people in 35 countries with net sales of over € 6 billion. Our two global company brands Skretting (aquafeed) and Trouw Nutrition (animal nutrition) have sales in over 90 countries. Innovation sits at the very heart of Nutreco’s business and culture. Through our strategic innovation and investment division Nutreco NuFrontiers, we look to identify, develop and invest in next generation, sustainable products, models and services throughout the feed and food protein value chain. NuFrontiers invests both in start-ups developing new technologies, ingredients or formulations, and joint-ventures and partnerships to create ‘moonshot projects’ that address major bottlenecks in the feed and food value chain. For more information visit www.nutreco.com and www.nutreconufrontiers.com
Stonehaven Incubate
Website: www.stonehaven-incubate.com
Stonehaven Incubate is a vehicle for human health companies to work with experienced executives to be able to expand their innovations into the animal health sector. With the animal health market estimated to grow between five and six per cent per annum and be worth in excess of US$30 billion by 2020, Dr Mark Heffernan, CEO, believes there is a growing need for innovation in a consolidating animal health industry. As a result, animal health companies are becoming more reliant on external innovators, with human health biotechs pioneering much of the disruptive technology.
However, he says that human health start-ups with potential animal health-related technologies often require the specialised animal health experience, networks or insights to be able to successfully fund, develop, and ultimately exit the business.
Stonehaven Incubate provides support across all these areas and draws on the global network and resources of its parent company, Stonehaven Holdings AG. Dr Heffernan himself also brings extensive experience of product development and capital-raising for both human and animal health companies.
Bank of America
Bank of America is one of the world’s leading financial institutions, serving individual consumers, small and middle-market businesses and large corporations with a full range of banking, investing, asset management and other financial and risk management products and services. The company provides unmatched convenience in the United States, serving approximately 67 million consumer and small business clients with approximately 4,200 retail financial centers, approximately 16,000 ATMs, and award-winning digital banking with approximately 41 million active users, including approximately 33 million mobile users. Bank of America is a global leader in wealth management, corporate and investment banking and trading across a broad range of asset classes, serving corporations, governments, institutions and individuals around the world. Bank of America offers industry-leading support to approximately 3 million small business households through a suite of innovative, easy-to-use online products and services. The company serves clients through operations across the United States, its territories and approximately 35 countries. Bank of America Corporation stock (NYSE: BAC) is listed on the New York Stock Exchange.
PetMedix
Website: https://www.petmedix.com/
Building on more than 30 years of world-leading innovation and human therapeutic drug development, PetMedix is applying the cutting edge of science to bring breakthroughs for much-loved pets worldwide.
The bond we have with our dogs and cats is a special one, they share our homes and are such an important part of our lives. Unfortunately, they also share many of our health problems, and can suffer from similar diseases and conditions to us. Whilst it is possible to give some types of human medicines to pets, it is not possible to do so with therapeutic antibodies – the pet’s immune system would reject them. What this means is that there are many of these conditions, including cancer, arthritis and allergies that we can successfully treat in people but where pets are continuing to suffer.
PetMedix is creating the treatment solutions to help our pets. By taking the experience of our scientific team, and decades of human clinical research, we are building platforms that can develop fully species-specific, naturally-generated therapeutic antibodies. We will use these platforms to develop our own veterinary medicines to target some of the most important underserved clinical areas, which not only would have critically beneficial healthcare impact, they also represent excellent market opportunities.
Media Partners
IAHJ - International Animal Health Journal
Website: www.animalhealthmedia.com
IAHJ - International Animal Health Journal is a Peer reviewed by our carefully selected editorial advisory panel, and extensive research network, IAHJ reports on Regulations & Validation, Drug Discovery, Development & Delivery, Clinical Research, Nutrition & Infectious Diseases, Custom & Contract Manufacturing, Primary & Secondary Packaging, Logistics & Supply Chain Management, and Marketing & Authorisation of all Drugs, Devices and Food Products that are used in the treatment of animals.
eFeed Link
Website: www.efeedlink.com
All About Feed
Website: www.allaboutfeed.net
All About Feed is a true multimedia brand, bringing you the latest developments in animal nutrition, diet formulation, and feed processing equipment. We deliver the best articles right in your inbox - subscribe for our e-mail newsletter by clicking here.
Pet Business World
Website: www.petbusinessworld.co.uk
Pet Business World is the UK’s leading news magazine and website for the pet and aquatics industry. We distribute 7,711 copies (November 2018) to qualifying pet trade professionals – the biggest circulation in the specialist trade by a considerable margin. The independently-owned magazine was established in 1951 and the website (www.petbusinessworld.co.uk) attracted more than 37 million hits in the 12 months to October 2018 – and rising!
Global Animal Health Network
Website: https://www.globalanimalhealthnetwork.com/
Global Animal Health Network saw the need in our industry to create a platform where all can access content created by our community, for our community. Information and resources should be accessible for all in the animal health industry. That's why they have created this channel for global collaboration and cutting edge news.
They are flipping the script on "how it's always been done" and want to showcase and highlight stories of our industry. Whether you're an entrepreneur, a recent graduate, or a seasoned veteran, you belong here.
Popular Pig Podcast
Website: https://popularpig.com/
Popular Pig provides invaluable information on the latest trends, news, and research from various experts that guide the global pork industry.
Become a partner
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920, email Stephen Swarray at [email protected], Harrison Sharp at [email protected] or downloading our agenda and clicking the "Interested in Sponsorship" box below.
Press Partnerships
Whether you are an association, embassy, industry body or publication, we can offer a tailored marketing partnership to suit your needs. As a Media Partner we can:
- Promote your organisation as an event partner across all conference materials, including the website, brochure, emails and on-site programme
- Offer your members or readers a discount on their registration fee for Animal Health Investment Europe
- Provide one free press pass to attend
- Distribute promotional materials at the conference
If you are a registered industry journalist or member of the press and would like to arrange an interview with a speaker or to discuss the event please contact:
Sarah Rowlands
Marketing Director
E: sarah.rowlands@kisacoresearch.com
Photo Gallery
View photos of Animal Health, Nutrition and Technology Innovation events over the years! View the full photo gallery here.
- Please note that a £49 processing fee will apply to any invoices requested.
- Any questions about your registration, please call +44 (0)20 3696 2920 or email us at [email protected].
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discounts or offers can be combined.
- Please view our Cancellation Policy.
- Emerging Companies are defined as early to mid-stage animal health pharmaceutical or biotech companies that are actively seeking financial investment or product licensing/acquisition. They must be engaged with this company on a full time basis. Those offering consultancy or market intelligence services do not qualify for this rate.
- Please Note: No additional discounts are available on ‘Emerging Company’ pricing.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.